Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 4/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344464 | 0.90 | HTR2A (0.73) | HTR2AHTR2CHTR2BMEN1TSHR | |
| SCHEMBL6154035 | 0.89 | HTR2A (0.69) | GAAHTR2AHTR2CHTR2BMEN1 | |
| SCHEMBL6209404 | 0.86 | HTR2A (0.66) | HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL10963541 | 0.86 | KCNH2 (0.73) | GAAHTR2AHTR2CHTR2BMEN1 | |
| SCHEMBL228242 | 0.86 | HTR2A (0.76) | HTR2AHTR2CHTR2BSLC18A3 | |
| SCHEMBL6070072 | 0.83 | GAA (0.70) | GAAOPRK1MEN1KMT2ADRD2 | |
| SCHEMBL6154047 | 0.83 | LTA4H (0.67) | GAA | |
| SCHEMBL4042398 | 0.83 | HTR2A (0.62) | HTR2AHTR2CHTR2BSLC18A3DRD2 | |
| SCHEMBL30516673 | 0.83 | SLC18A3 (0.74) | HTR2AHTR2CHTR2BMEN1TSHR | |
| SCHEMBL5539621 | 0.83 | SIGMAR1 (0.65) | HTR2AHTR2CHTR2BDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GAA 2875/4885HTR2A 1910/4885HTR2C 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.